Profile data is unavailable for this security.
About the company
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
- Revenue in USD (TTM)598.70m
- Net income in USD-14.06m
- Incorporated2002
- Employees499.00
- LocationAmicus Therapeutics Inc47 Hulfish StreetPRINCETON 08542United StatesUSA
- Phone+1 (609) 662-2000
- Fax+1 (609) 662-2001
- Websitehttps://www.amicusrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grail Inc | 141.83m | -406.24m | 3.80bn | 1.00k | -- | 1.57 | -- | 26.80 | -11.63 | -11.63 | 4.06 | 61.94 | 0.0496 | -- | 9.01 | 141,827.00 | -14.21 | -49.71 | -14.65 | -50.85 | 46.88 | 39.69 | -286.43 | -3,510.18 | -- | -- | 0.00 | -- | 34.90 | -- | -38.30 | -- | 9.34 | -- |
| Arcellx Inc | 35.90m | -217.90m | 3.96bn | 163.00 | -- | 8.98 | -- | 110.34 | -3.92 | -3.92 | 0.6462 | 7.63 | 0.0505 | -- | 9.57 | 220,233.10 | -30.67 | -27.24 | -37.39 | -32.13 | -- | -- | -607.01 | -212.50 | -- | -- | 0.00 | -- | -2.16 | -- | -51.86 | -- | 28.52 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -94.44m | 4.01bn | 59.00 | -- | 11.64 | -- | -- | -1.03 | -1.03 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -27.78 | -32.69 | -28.92 | -35.03 | -- | -- | -- | -33,013.70 | -- | -- | 0.00 | -- | -- | -- | 1.50 | -- | -45.82 | -- |
| Crinetics Pharmaceuticals Inc | 1.54m | -423.10m | 4.05bn | 437.00 | -- | 3.77 | -- | 2,639.66 | -4.53 | -4.53 | 0.0165 | 11.34 | 0.0014 | -- | 0.2622 | 3,512.59 | -39.66 | -36.96 | -42.19 | -39.20 | -- | -- | -27,563.32 | -7,785.98 | -- | -- | 0.00 | -- | -74.11 | -2.73 | -39.10 | -- | 50.86 | -- |
| BillionToOne Inc | -100.00bn | -100.00bn | 4.06bn | -- | -- | -- | -- | -- | -- | -- | -- | 4.02 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.75 | -- | 0.238 | -- | 112.72 | -- | 49.72 | -- | -- | -- |
| CG Oncology Inc | 2.17m | -151.48m | 4.15bn | 113.00 | -- | 5.86 | -- | 1,910.91 | -2.03 | -2.03 | 0.0292 | 8.78 | 0.0034 | -- | 6.67 | 19,238.94 | -23.63 | -- | -24.51 | -- | 4.09 | -- | -6,967.99 | -- | 22.74 | -- | 0.0043 | -- | 458.33 | -- | -29.85 | -- | -- | -- |
| Gyroscope Therapeutics Holdings Ltd(ADR) | -100.00bn | -100.00bn | 4.25bn | 167.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -70.87 | -- | -58.56 | -- | -- | -- |
| Amicus Therapeutics, Inc. | 598.70m | -14.06m | 4.49bn | 499.00 | -- | 19.16 | -- | 7.50 | -0.0458 | -0.0458 | 1.94 | 0.7469 | 0.7234 | 0.4175 | 5.65 | 1,199,808.00 | -1.70 | -23.63 | -2.17 | -28.66 | 89.77 | 89.34 | -2.35 | -53.29 | 2.09 | 0.8067 | 0.6298 | -- | 32.29 | 23.72 | 62.99 | -- | -29.23 | -- |
| Apogee Therapeutics Inc | 0.00 | -253.67m | 4.63bn | 196.00 | -- | 6.86 | -- | -- | -4.36 | -4.36 | 0.00 | 9.89 | 0.00 | -- | -- | 0.00 | -36.18 | -- | -37.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -116.88 | -- | -- | -- |
| Scholar Rock Holding Corp | 0.00 | -353.43m | 4.69bn | 196.00 | -- | 18.61 | -- | -- | -3.15 | -3.15 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -119.63 | -45.06 | -144.40 | -51.62 | -- | -- | -- | -1,134.62 | -- | -- | 0.2891 | -- | -- | -- | -48.56 | -- | -49.93 | -- |
| Celcuity Inc | 0.00 | -162.72m | 4.84bn | 87.00 | -- | 38.67 | -- | -- | -3.67 | -3.67 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -43.45 | -42.61 | -47.58 | -45.75 | -- | -- | -- | -- | -- | -48.30 | 0.7325 | -- | -- | -- | -75.26 | -- | -8.05 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -210.69m | 4.84bn | 218.00 | -- | -- | -- | -- | -3.65 | -3.65 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -23.87 | -- | -25.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -36.72 | -- | -- | -- |
| Protagonist Therapeutics Inc | 209.22m | 45.91m | 5.09bn | 128.00 | 129.07 | 7.88 | 107.59 | 24.35 | 0.6313 | 0.6313 | 3.26 | 10.34 | 0.3205 | -- | 52.34 | 1,660,452.00 | 7.03 | -7.11 | 7.55 | -7.93 | -- | -- | 21.94 | -21.29 | -- | -- | 0.00 | -- | 624.06 | 351.71 | 448.54 | -- | 6.98 | -- |
| Immunovant Inc | 0.00 | -464.20m | 5.24bn | 362.00 | -- | 5.31 | -- | -- | -2.68 | -2.68 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -63.01 | -47.00 | -69.35 | -51.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -59.58 | -- | 89.57 | -- |
Data as of Feb 13 2026. Currency figures normalised to Amicus Therapeutics Inc's reporting currency: US Dollar USD
42.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 27.18m | 8.66% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 21.98m | 7.01% |
| Avoro Capital Advisor LLCas of 30 Sep 2025 | 15.03m | 4.79% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 14.83m | 4.73% |
| Millennium Management LLCas of 30 Sep 2025 | 11.81m | 3.77% |
| William Blair Investment Management LLCas of 31 Dec 2025 | 10.63m | 3.39% |
| Vestal Point Capital LPas of 30 Sep 2025 | 9.75m | 3.11% |
| Citadel Advisors LLCas of 30 Sep 2025 | 8.19m | 2.61% |
| Geode Capital Management LLCas of 31 Dec 2025 | 7.35m | 2.34% |
| Point72 Asset Management LPas of 30 Sep 2025 | 7.21m | 2.30% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
